 |
Clinical TrialsDana-Farber/Children's Hospital Cancer Care (DF/CHCC) is one of the top pediatric cancer programs in the country. The researchers at Dana-Farber Cancer Institute and Children's Hospital Boston initiate multiple new pediatric cancer clinical studies each year to investigate new treatments for all forms of childhood cancer. Many of our findings have built the foundation for new and improved cancer therapies. In addition, many DF/CHCC investigators assume leadership roles in national cooperative research groups. Our researchers participate in trials overseen by the Children's Oncology Group, DFCI ALL Consortium, Histiocyte Society, Pediatric Brain Tumor Consortium, Pediatric Blood & Marrow Transplant Consortium, and New Approaches to Neuroblastoma Therapy Consortium. DF/CHCC is the only pediatric program in New England that offers access to many Phase I studies overseen by these collaborative organizations. At any time there is an average of 60 unique clinical trials accepting new patients at DF/CHCC, each of which investigates a new way to treat cancer. You can learn more about clinical trials available through DF/CHCC by visiting the specific program and service of interest, through our online listing, or by calling Click here to see our most recent Clinical Trial Update, which highlights select protocols for the treatment of pediatric hematologic and oncologic disorders. To receive future educational and research updates, please register online at www.danafarberchildrens.org/contact. |